

=> d his

(FILE 'HOME' ENTERED AT 10:52:06 ON 08 DEC 2003)

FILE 'CAPLUS' ENTERED AT 10:55:19 ON 08 DEC 2003

FILE 'REGISTRY' ENTERED AT 10:55:25 ON 08 DEC 2003

L1 1 S 59-05-2

FILE 'REGISTRY' ENTERED AT 10:56:13 ON 08 DEC 2003

L2 1 S 59-05-2/RN
SET NOTICE 1 DISPLAY
SET NOTICE LOGIN DISPLAY

FILE 'REGISTRY' ENTERED AT 11:00:57 ON 08 DEC 2003

L3 SET TERMSET E#
DEL SEL Y
SEL L2 1 RN
1 S E1/RN
SET TERMSET LOGIN

FILE 'CAPLUS' ENTERED AT 11:01:01 ON 08 DEC 2003

L4 10281 S L3
L5 103 S L4 AND PY<=2001 AND ((SUBARACHNOID(2A)HEMORRHAGE) OR TRAUMA O

FILE 'REGISTRY' ENTERED AT 11:03:53 ON 08 DEC 2003

L6 SET TERMSET E#
DEL SEL Y
SEL L2 1 RN
1 S E1/RN
SET TERMSET LOGIN

FILE 'USPATFULL' ENTERED AT 11:03:57 ON 08 DEC 2003

L7 1079 S L6
L8 133 S L7 AND PY<=2000 AND ((SUBARACHNOID(2A)HEMORRHAGE) OR TRAUMA O
L9 10 S L2 AND ((SUBARACHNOID(2A)HEMORRHAGE) OR CEREBRAL(2A)VASOPASME
L10 17697 S METHOTREXATE OR AMETHOPTERIN? OR ANTIFOLAN OR CL(W)14377 OR E
L11 194 S L10(S) ((SUBARACHNOID(2A)HEMORRHAGE) OR CEREBRAL(2A)VASOPASME
L12 0 S L11 NOT PY>=2000
L13 0 S L11 NOT PY>=2001

FILE 'EUROPATFULL, PATDPAFULL, PCTFULL, RDISCLOSURE, USPATFULL, USPAT2'
ENTERED AT 12:00:50 ON 08 DEC 2003

L14 7 S L13
L15 1769 S L10(L) ((SUBARACHNOID(2A)HEMORRHAGE) OR CEREBRAL(2A)VASOPASME

FILE 'USPATFULL' ENTERED AT 12:06:06 ON 08 DEC 2003

L16 853 S L15
L17 54 S L16 NOT PY>=2000

L9 ANSWER 9 OF 10 USPATFULL on STN

SUMM . . . conditions, uveitis, meningitis, inflammatory bowel disease, myositis, inflammation of oral and esophageal tissues, inflammatory lung disease, inflammation associated with myocardial **infarction** and **cerebral** vascular disease or accidents, trauma induced inflammation, and other inflammatory/immune disorders.

IT 50-18-0, Cyclophosphamide 50-23-7, Hydrocortisone 50-35-1, Thalidomide 59-05-2, Methotrexate 446-86-6, Azathioprine 50924-49-7, Mizoribine 53123-88-9, Rapamycin 59865-13-3, Cyclosporine 77327-05-0, Didemnin B 89149-10-0, Deoxyspergualin 104987-11-3, Tacrolimus
(topical compns. contg. immunosuppressants alone or in combination with inflammation inhibitors for induction of site-specific immunosuppression)

L9 ANSWER 10 OF 10 USPATFULL on STN

DETD . . . Examples of specific types of abnormal brain tissue include gliomas, metastatic brain tumors, head injury, meningitis, brain abscess, multiple sclerosis, **subarachnoid hemorrhage**

IT 59-05-2, Methotrexate 15663-27-1, Cisplatin
(bradykinin and analog RMP-7 for opening of abnormal brain tissue capillaries for selective passage of neuropharmaceuticals)

L17 ANSWER 9 OF 54 USPATFULL on STN

SUMM . . . segmental or intercostal neuralgia and other neuralgias; and cerebral vascular disorders due to acute or chronic cerebrovascular damage such as **cerebral infarction**, subarachnoid haemorrhage or cerebral oedema.

SUMM . . . cisplatin, dacarbazine (DTIC), dactinomycin, mechlorethamine (nitrogen mustard), streptozocin, cyclophosphamide, carmustine (BCNU), lomustine (CCNU), doxorubicin (adriamycin), daunorubicin, procarbazine, mitomycin, cytarabine, etoposide, **methotrexate**, 5-fluorouracil, vinblastine, vincristine, bleomycin and chlorambucil [R. J. Gralla et al in Cancer Treatment Reports (1984) 68(1), 163-172].

L17 ANSWER 10 OF 54 USPATFULL on STN

DETD . . . animal. A stroke is a blockage or hemorrhage of a blood vessel in or leading to the brain (e.g., aneurysmal **subarachnoid hemorrhage**) that causes inadequate blood supply (ischemia) to the brain. After brain ischemia, leukocytes adhere to the perturbed vascular endothelium and. . .

DETD . . . mitoxantrone, amsacrine, chlorambucil, nitrogen mustards, methylcyclohexylnitrosurea, melphalan, cyclophosphamide, 6-mercaptopurine, 6-thioguanine, cytarabine (CA), 5-azacytidine, hydroxyurea, deoxycoformycin, 5-fluorouracil (5-FU), 4-hydroxyperoxycyclophosphoramide, 5-fluorodeoxyuridine (5-FUdR), **methotrexate** (MTX), colchicine, vincristine, vinblastine, etoposide, trimetrexate, teniposide, cisplatin and diethylstilbestrol (DES). (See, generally, The Merck Manual of Diagnosis and Therapy,. . .

DETD . . . (NSAIDS), including indomethacin, ibuprofen, fenopofen, ketoprofen, naproxen, piroxicam, phenylbutazone, oxyphenbutazone, sulindac and meclofenamate; gold compounds, such as auranofin; D-penicillamine; cyclophosphamide; **methotrexate**; azathioprine; colchicine; hydroxychloroquine; corticotropin; steroids and corticosteroids such as, for example, hydrocortisone, deoxyhydrocortisone, fludrocortisone, prednisolone, methylprednisolone, prednisone, triamcinolone, dexamethasone, betamethasone. . .

L9 ANSWER 6 OF 10 USPATFULL on STN

DETD treat apoptosis associated with reperfusion damage involved in a variety of conditions, including, but not limited to, coronary artery obstruction; **cerebral infarction**; spinal/head trauma and concomitant severe paralysis; reperfusion damage due to other insults such as frostbite; and any indication previously thought. . . .

DETD Myocardial and **cerebral infarctions** are caused generally by a sudden insufficiency of arterial or venous blood supply due to emboli, thrombi, or pressure that. . . .

DETD The invention further encompasses a method of reducing the apoptosis and reperfusion damage associated with myocardial and **cerebral infarctions** for patients with a high risk of heart attack and stroke by administering a therapeutically effective amount of at least.

CLM What is claimed is:

49. The method according to claim 48 wherein the reperfusion is associated with coronary artery obstruction; **cerebral infarction**; spinal/head trauma and concomitant severe paralysis; and frostbite.

=> e methotrexate/cn

E1 1 METHOTHYRIN/CN
E2 1 METHOTREXAT-EBEWE/CN
E3 1 --> METHOTREXATE/CN
E4 1 METHOTREXATE .ALPHA., .GAMMA.- (1-TETRADECANOYL-2-HEXANOYLPHOSPHATIDYLETHANOLAMINE)/CN
E5 1 METHOTREXATE .ALPHA., .GAMMA.- (DITETRADECANOYLPHOSPHATIDYLETHANOLAMINE)/CN
E6 1 METHOTREXATE .ALPHA., .GAMMA.-BIS(L-GLUTAMATE TETRAETHYL ESTER)/CN
E7 1 METHOTREXATE .ALPHA., .GAMMA.-DIHEXANOYLPHOSPHATIDYLETHANOLAMINE/CN
E8 1 METHOTREXATE .ALPHA.- (1-TETRADECANOYL-2-HEXANOYLPHOSPHATIDYLETHANOLAMINE)/CN
E9 1 METHOTREXATE .ALPHA.- (DITETRADECANOYLPHOSPHATIDYLETHANOLAMINE)/CN
E10 1 METHOTREXATE .ALPHA.-DIHEXANOYLPHOSPHATIDYLETHANOLAMINE/CN
E11 1 METHOTREXATE .ALPHA.-L-GLUTAMATE DIETHYL ESTER/CN
E12 1 METHOTREXATE .ALPHA.-METHYL ESTER/CN


=> s e3

L1 1 METHOTREXATE/CN

=> d rn str cn

L1 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2003 ACS on STN
RN 59-05-2 REGISTRY

Absolute stereochemistry.



*Electron
space*

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

CN L-Glutamic acid, N-[4-[[[(2,4-diamino-6-pteridiny]methyl]methylamino]benzoyl]- (9CI) (CA INDEX NAME)

OTHER CA INDEX NAMES:

CN Glutamic acid, N-[p-[[[(2,4-diamino-6-pteridiny]methyl]methylamino]benzoyl]-, L-(+)- (8CI)

OTHER NAMES:

CN (+)-Amethopterin
CN 4-Amino-10-methylfolic acid
CN 4-Amino-N10-methylfolic acid
CN 4-Amino-N10-methylpteroylglutamic acid
CN Amethopterin
CN Amethopterin
CN Antifolan
CN CL 14377
CN EMT 25299
CN Emtexate
CN L-Amethopterin
CN L-Methotrexate

CN	Ledertrexate
CN	Metatrexan
CN	Methotrexat-Ebewe
CN	Methotrexate
CN	Methylaminopterin
CN	Mexate
CN	MTX
CN	N- [p- [[2,4-Diamino-6-pteridiny]methyl)methylamino]benzoyl] -L- (+) -glutamic acid
CN	NSC 740
CN	R 9985
CN	Rheumatrex